Non-small-cell lung cancer: Then and now

Journal of Clinical Oncology

Volumn 31, Issue 8, 2013, Pages 981-983

  Schiller, Joan H ^a   Gandara, David R ^b   Goss, Glenwood D ^c   Vokes, Everett E ^d  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; LOMUSTINE; METHOTREXATE; VINCRISTINE;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG SCREENING; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; PATIENT CARE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; HUMANS; LUNG NEOPLASMS; MASS SCREENING; NEOPLASM STAGING; PERIODICALS AS TOPIC; PUBLISHING; TUMOR MARKERS, BIOLOGICAL;

EID: 84875955635     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.5772     Document Type: Editorial

References (31)

1. Goodman GE, Miller TP, Manning MM, et al: Treatment of small-cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy. J Clin Oncol 1:483-488, 1983 (Pubitemid 13020048)
2. Dillman RO, Seagren SL, Taetle R: Failure of low-dose, total-body irradiation to augment combination chemotherapy in extensive-stage small cell carcinoma of the lung. J Clin Oncol 1:242-246, 1983 (Pubitemid 14189662)
3. Woodcock TM, Blumenreich MS, Richman SP, et al: Combination chemotherapy with cisdiamminedichloroplatinum and vinblastine in advanced non-small cell lung cancer. J Clin Oncol 1:247-250, 1983 (Pubitemid 14189663)
4. Fuks JZ, Aisner J, Van Echo DA, et al: Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer. J Clin Oncol 1:295-301, 1983 (Pubitemid 14176707)
5. Green M, Horton C, Spaulding M, et al: Fourdrug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: A Cancer and Leukemia Group B study. J Clin Oncol 1:559- 565, 1983 (Pubitemid 14235259)
6. Groen HJ, Sietsma H, Vincent A, et al: Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 study. J Clin Oncol 29:4320-4326, 2011
7. Socinski MA, Bondarenko I, Karaseva NA, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 30:2055-2062, 2012
8. Lara PN Jr, Douillard JY, Nakagawa K, et al: Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965- 2971, 2011
9. Niell HB, Herndon JE 2nd, Miller AA, et al: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23:3752- 3759, 2005
10. Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122, 2001 (Pubitemid 32366966)
11. Goldstraw P: New staging system: How does it affect our practice? J Clin Oncol 31:984- 991, 2013
12. Travis WD, Brambilla E, Riely GJ: New pathological classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol 31: 992-1001, 2013
13. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
14. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395-409, 2011
15. Aberle DR, Abtin F, Brown K: Computed tomography screening for lung cancer: Has it finally arrived? Implications of the National Lung Screening Trial. J Clin Oncol 31:1002-1008, 2013
16. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
17. Gerber DE, Schiller JH: Maintenance chemotherapy for advanced non-small-cell lung cancer: New life for an old idea. J Clin Oncol 31:1009-1020, 2013
18. Brahmer JR: Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 31:1021-1028, 2013
19. Salama JK, Vokes EE: New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 31:1029-1038, 2013
20. Li T, Kung H-J, Mack PC, et al: Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J Clin Oncol 31:1039-1049, 2013
21. Besse B, Olaussen KA, Soria J-C: ERCC1 and RRM1: Ready for prime time? J Clin Oncol 31:1050- 1060, 2013
22. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004 (Pubitemid 38637993)
23. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497- 1500, 2004 (Pubitemid 38720929)
24. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380- 2388, 2010
25. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
26. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
27. Laurie SA, Goss GD: Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol 31:1061-1069, 2013
28. Ohashi K, Maruvka YE, Michor F, et al: Epidermal growth factor receptor tyrosine kinase inhibitor- resistant disease. J Clin Oncol 31:1070-1080, 2013
29. Mok T, Yang J-J, Lam K-C: Treating patients with EGFR-sensitizing mutations: First line or second line-Is there a difference? J Clin Oncol 31: 1081-1088, 2013
30. Sadiq AA, Salgia R: MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31:1089- 1096, 2013
31. Oxnard GR, Binder A, Janne PA: New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31:1097-1104, 2013 DOI: 10.1200/JCO.2012.47.5772;